People using semaglutide for diabetes or weight loss have also reported experiencing a reduced desire for alcohol. A new ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

semaglutide outperform Rybelsus®-semaglutide with its proprietary SNAC technology in measures of blood sugar control or weight loss? Does DehydraTECH processing enhance real world outcomes such ...

The drugmaker behind the medical phenomenon semaglutide ... weight loss drug, CagriSema, disappointed in weight loss trials. The GLP-1-based drug only helped participants shed an average of ...

Semaglutide ... weight-loss and boost other areas of patient health. Data from a keenly-anticipated trial of its CagriSema drug recently disappointed investors as patients lost an average of ...